AbCellera Biologics (ABCL) vs Xenon Pharmaceuticals (XENE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AbCellera Biologics (ABCL) has outperformed Xenon Pharmaceuticals (XENE) over the past year, gaining 94.8% versus a loss of 7.9%. Over five years, XENE leads with a +7.4% price change compared with -22.6% for ABCL. AbCellera Biologics is the larger company by market cap ($3.90 billion vs $3.50 billion), about 1.1 times the size.
AbCellera Biologics converts more of its revenue into profit, with a net margin of -194.9% versus -4612.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABCL | XENE |
|---|---|---|
| Share price | $12.02 | $36.16 |
| Market cap | $3.90B | $3.50B |
| 1-day change | -6.31% | -0.69% |
| YTD return | +251.46% | -19.32% |
| 1-year return | +94.81% | -7.87% |
| 5-year return | -22.60% | +7.43% |
| EPS (TTM) | $-0.54 | $-4.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.13M | $7.50M |
| Revenue growth (YoY) | +160.56% | — |
| Net income (latest FY) | $-146.41M | $-345.91M |
| Operating margin | -288.98% | -4974.27% |
| Net margin | -194.88% | -4612.13% |
| 52-week high | $15.02 | $72.66 |
| 52-week low | $2.75 | $35.06 |
| Distance from 52-week high | -19.95% | -50.23% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +38.94% | +102.90% |
| Average volume | 6.67M | 1.43M |
| Shares outstanding | 324.05M | 96.84M |
| Employees | 562 | 358 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABCL has outperformed XENE by 102.7 percentage points over the past year.
- AbCellera Biologics is more profitable, keeping -194.9 cents of every revenue dollar as net income versus -4612.1 cents for Xenon Pharmaceuticals.
About AbCellera Biologics
ABCL stock →AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees
About Xenon Pharmaceuticals
XENE stock →Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 358 employees
ABCL vs XENE FAQ
Which is bigger, AbCellera Biologics or Xenon Pharmaceuticals?
AbCellera Biologics (ABCL) is larger, with a market capitalization of $3.90B compared with $3.50B for Xenon Pharmaceuticals (XENE).
Which stock has performed better over the past year, ABCL or XENE?
ABCL returned +94.81% over the past 12 months, compared with -7.87% for XENE (price return, excluding dividends). Past performance does not predict future results.
Are AbCellera Biologics and Xenon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.